Erste Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Erste Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.55M	Buy	21,000 +7,500	+56%	+$783K	0.02%	355
2026 Q1	$1.35M	Hold	13,500	–	–	0.01%	415
2025 Q4	$1.19M	Hold	13,500	–	–	0.01%	422
2025 Q3	$879K	Hold	13,500	–	–	0.01%	426
2025 Q2	$752K	Hold	13,500	–	–	0.01%	553
2025 Q1	$660K	Hold	13,500	–	–	0.01%	411
2024 Q4	$526K	Buy	+13,500	New	+$589K	0.01%	436

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Erste Asset Management's PTGX Position: Q2 2026 in Review

Erste Asset Management increased its Protagonist Therapeutics (PTGX) stake by 56% in Q2 2026, buying an estimated $783K and bringing the position to 21,000 shares worth $2.55M. The position accounts for 0.02% of the portfolio, ranked #355.

Erste Asset Management first reported a position in PTGX in Q4 2024 and has held it in 7 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Erste Asset Management held 21,000 shares of Protagonist Therapeutics worth $2.55M as of Q2 2026.
Erste Asset Management bought 7,500 Protagonist Therapeutics shares in Q2 2026, an estimated $783K.
Protagonist Therapeutics made up 0.02% of Erste Asset Management's portfolio in Q2 2026, its #355 holding.
Erste Asset Management first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 7 quarters since.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.